Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin. The pattern of recurrence in 9 patients has been altered favorably. Although the findings are still preliminary they appear to hold promise of a new therapeutic approach to the treatment of a group of neoplasms for which effective therapy is still lacking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunotherapy of guinea pig cancer with bcg
Zbar, B., & Rapp, H. J. (1974) · Cancer · doi:10.1002/1097-0142(197410)34:8+<1532::aid-cncr2820340827>3.0.co;2-h · Cited by 114
INCREASED CYTOLYTIC ACTIVITY OF A SUBCELLULAR FRACTION FROM MOUSE LIVER AFTER B.C.G. INFECTION
Ferluga, J. (1973) · The Lancet · doi:10.1016/s0140-6736(73)92734-7 · Cited by 8
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Babjuk, M., Burger, M., Capoun, O., Cohen, D., Compérat, E. M., Dominguez Escrig, J. L., Gontero, P., Liedberg, F., Masson-Lecomte, A., Mostafid, A. H., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.08.010 · Cited by 1,615
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Babjuk, M., Burger, M., Compérat, E. M., Gontero, P., Mostafid, A. H., Palou, J., van Rhijn, B. W. G., Rouprêt, M., Shariat, S. F., Sylvester, R., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.08.016 · Cited by 1,297
Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
Duan, T., Du, Y., Xing, C., Wang, H. Y., & Wang, R.-F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812774 · Cited by 972
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Kraehenbuehl, L., Weng, C.-H., Eghbali, S., Wolchok, J. D., & Merghoub, T. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00552-7 · Cited by 846
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
The mechanism of action of BCG therapy for bladder cancer--a current perspective
Redelman-Sidi, G., Glickman, M. S., & Bochner, B. H. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.15 · Cited by 729
Toll-like receptors in immunity and inflammatory diseases: Past, present, and future
Vijay, K. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.002 · Cited by 643
Inflammation as a Tumor Promoter in Cancer Induction
Philip, M., Rowley, D. A., & Schreiber, H. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.006 · Cited by 640
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Flaig, T. W., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Chang, S., Downs, T. M., Efstathiou, J. A., Friedlander, T., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0011 · Cited by 626
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome
Cookson, M. S., Herr, H. W., Zhang, Z.-F., Soloway, S., Sogani, P. C., & Fair, W. R. (1997) · Journal of Urology · doi:10.1097/00005392-199707000-00017 · Cited by 549
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 544
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Oddens, J., Brausi, M., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., Gontero, P., Hoeltl, W., Turkeri, L., Marreaud, S., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.10.039 · Cited by 520
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Melero, I., Castanon, E., Alvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 493
Cancer and the Immune System: The History and Background of Immunotherapy
Abbott, M., & Ustoyev, Y. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.08.002 · Cited by 489
BCG immunotherapy of bladder cancer: 20 years on
Alexandroff, A. B., Jackson, A. M., O'Donnell, M. A., & James, K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07422-4 · Cited by 471
From bench to bedside: the history and progress of CAR T cell therapy
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., & He, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188049 · Cited by 466
The Intriguing History of Cancer Immunotherapy
Dobosz, P., & Dzieciątkowski, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02965 · Cited by 458
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
Pettenati, C., & Ingersoll, M. A. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0055-4 · Cited by 457
Cancer immunotherapy – revisited
Lesterhuis, W. J., Haanen, J. B. A. G., & Punt, C. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3500 · Cited by 427
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Zhang, H., Liu, L., Liu, J., Dang, P., Hu, S., Yuan, W., Sun, Z., Liu, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01725-x · Cited by 389
Brausi, M., Oddens, J., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., Gontero, P., Turkeri, L., Marreaud, S., Collette, S., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.07.021 · Cited by 389
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
Bellmunt, J., Powles, T., & Vogelzang, N. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.007 · Cited by 374
Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead
Oiseth, S. J., & Aziz, M. S. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.41 · Cited by 369
History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success Story
Herr, H. W., & Morales, A. (2008) · Journal of Urology · doi:10.1016/j.juro.2007.08.122 · Cited by 353
Self-citationShelley, M. D., Wilt, T. J., Court, J., Coles, B., Kynaston, H., & Mason, M. D. (2004) · BJU International · doi:10.1111/j.1464-410x.2003.04655.x · Cited by 342
Bacillus Calmette-guerin Immunotherapy of Superficial Bladder Cancer
Lamm, D. L., Thor, D. E., Harris, S. C., Reyna, J. A., Stogdill, V. D., & Radwin, H. M. (1980) · Journal of Urology · doi:10.1016/s0022-5347(17)55282-9 · Cited by 333
The Yin and Yang of Toll-like receptors in cancer
Pradere, J.-P., Dapito, D. H., & Schwabe, R. F. (2014) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 331
Immune Mechanisms in Bacillus Calmette-Guerin Immunotherapy for Superficial Bladder Cancer
BÖHLE, A., & BRANDAU, S. (2003) · Journal of Urology · doi:10.1097/01.ju.0000073852.24341.4a · Cited by 318
Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder Carcinoma
Brosman, S. A. (1982) · Journal of Urology · doi:10.1016/s0022-5347(17)52736-6 · Cited by 314
Unconventional T Cell Targets for Cancer Immunotherapy
Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P., & Rossjohn, J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.009 · Cited by 314
Shelley, M. D., Kynaston, H., Court, J., Wilt, T. J., Coles, B., Burgon, K., & Mason, M. D. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02306.x · Cited by 313
The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
Urban-Wojciuk, Z., Khan, M. M., Oyler, B. L., Fåhraeus, R., Marek-Trzonkowska, N., Nita-Lazar, A., Hupp, T. R., & Goodlett, D. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02388 · Cited by 307
Pérez-Jacoiste Asín, M. A., Fernández-Ruiz, M., López-Medrano, F., Lumbreras, C., Tejido, Á., San Juan, R., Arrebola-Pajares, A., Lizasoain, M., Prieto, S., & Aguado, J. M. (2014) · Medicine · doi:10.1097/md.0000000000000119 · Cited by 303
Brausi, M., Witjes, J. A., Lamm, D., Persad, R., Palou, J., Colombel, M., Buckley, R., Soloway, M., Akaza, H., & Böhle, A. (2011) · Journal of Urology · doi:10.1016/j.juro.2011.07.076 · Cited by 296
T-Cell Subsets Required for Intravesical BCG Immunotherapy for Bladder Cancer
Ratliff, T. L., Ritchey, J. K., Yuan, J. J. J., Andriole, G. L., & Catalona, W. J. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)35678-1 · Cited by 283
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
Galli, F., Aguilera, J. V., Palermo, B., Markovic, S. N., Nisticò, P., & Signore, A. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01586-y · Cited by 278
Bladder Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines
Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Buyyounouski, M. K., Chan, K., Chang, S. S., Chang, P., Friedlander, T., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0024 · Cited by 273
Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
Biot, C., Rentsch, C. A., Gsponer, J. R., Birkhäuser, F. D., Jusforgues-Saklani, H., Lemaître, F., Auriau, C., Bachmann, A., Bousso, P., Demangel, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003586 · Cited by 269
Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer
Lamm, D. L. (2000) · Clinical Infectious Diseases · doi:10.1086/314064 · Cited by 264
Kamat, A. M., Flaig, T. W., Grossman, H. B., Konety, B., Lamm, D., O'Donnell, M. A., Uchio, E., Efstathiou, J. A., & Taylor, J. A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.58 · Cited by 252
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“Since Alvaro Morales used Bacillus Calmette Guerin (BCG) to treat superficial bladder cancer in 1976, therapeutic vaccines have emerged [122].”
MethodPD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s135157 · Cited by 144
“Bladder cancer has been known to be immunoresponsive since original reports by Morales et al on the activity of intravesical instillation of bacillus Calmette–Guérin (BCG) in NMIBC.”
Local heroes or villains: tissue-resident memory T cells in human health and disease
Sasson, S. C., Gordon, C. L., Christo, S. N., Klenerman, P., & Mackay, L. K. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0359-1 · Cited by 111
“Bladder cancer The successful use of the therapeutic intravesical bacillus Calmette-Guerin in bladder cancer demonstrates the capacity to stimulate a localized T cell-mediated antitumor response.(163) TRMlike TILs were found in local tissue from patients with bladder urothelial cancer,(56) and these cells had high exp…”
The probiotic approach: An alternative treatment option in urology
Hoesl, C. E., & Altwein, J. E. (2005) · European Urology · doi:10.1016/j.eururo.2004.09.011 · Cited by 78
BCG-Related Renal Granulomas Managed Conservatively
Al-Qaoud, T., Brimo, F., Aprikian, A. G., & Andonian, S. (2015) · Canadian Urological Association Journal · doi:10.5489/cuaj.2664 · Cited by 24
Mohammed, A., & Arastu, Z. (2017) · BMC Urology · doi:10.1186/s12894-017-0304-5 · Cited by 20
From mucosal infection to successful cancer immunotherapy
Goubet, A.-G., Rouanne, M., Derosa, L., Kroemer, G., & Zitvogel, L. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00784-5 · Cited by 11
Narita, K., Akita, H., Kikuchi, E., Nakahara, T., Okuda, S., Nakatsuka, S., Oya, M., & Jinzaki, M. (2019) · BJR|case reports · doi:10.1259/bjrcr.20190012 · Cited by 11
(1991) · doi:10.1002/1097-0142(19910615)67:12<3024::aid-cncr2820671216>3.0.co;2-q
Metadata
- Authors
- Morales, A., Eidinger, D., & Bruce, A. W.
- Venue
- Journal of Urology
- Published
- 2017-02
- Volume
- 197
- Issue
- 2S
- Pages
- 180-3
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2058331779
- Cited by
- 1,533
- References
- 2
- FWCI
- 86.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.